June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge
Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones Industrial Index slid 5%, 6% and 7%, respectively. The BioCentury 100 was off 4%, the NASDAQ Biotechnology Index (NBI) and NYSE Arca Biotech Index (BTK) were down 5%, and the S&P Biotech ETF (XBI) fell 6%.

Simcere lines up for Hong Kong IPO
Simcere Pharmaceutical Group Ltd. proposed to list on the Hong Kong stock exchange Wednesday in an offering underwritten by Morgan Stanley and CICC. The company’s oncology, neurology and autoimmune pipeline includes 50 candidates ranging from preclinical to late-stage development. Simcere joins the more than 40 biopharmas that have lined up for an IPO on U.S. and Asian exchanges (see “Next up on NASDAQ”)...